|
|||||
|
|
Retraction Note: miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization |
|
| Authors: | Lin Xiaobin Wang Shuyi Sun Min Zhang Chunxiao Wei Chen Yang Chaogang Dou Rongzhang Liu Qing Xiong Bin |
| Institution: | 1.International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Eastern
Hepatobiliary Surgery Institute/hospital, Shanghai, 200438, People’s Republic of China ;2.Department of Radiotherapy Oncology, General Hospital of Northern Theater Command, Shenyang, 110016, People’s Republic of China ;3.Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China ;4.Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen, People’s Republic of China ;5.Berry Oncology Corporation, Beijing, 100102, People’s Republic of China ;6.Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, People’s Republic of China ;7.Hepatology Department, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, 315010, People’s Republic of China ;8.Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, 247 Beiyuan Street, Jinan, 250033, Shandong, People’s Republic of China ;9.Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan, 250033, People’s Republic of China ;10.Xuzhou Infectious Diseases Hospital, Xuzhou, 221004, People’s Republic of China ;11.The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China ;12.Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People’s Republic of China ;13.Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, People’s Republic of China ;14.Department of Hepatology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, People’s Republic of China ;15.Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, People’s Republic of China ;16.Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, People’s Republic of China ;17.Department of Hepatobiliary Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 210822, People’s Republic of China ;18.The Department of Infectious Disease, The First People’s Hospital of Foshan, Foshan City, 528000, People’s Republic of China ;19.The First Hospital of Jilin University, Jilin, 130021, People’s Republic of China ;20.Chifeng Clinical Medical School of Inner, Mongolia Medical University, Chifeng, 024000, People’s Republic of China ;21.State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, People’s Republic of China ;22.Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai, 200438, People’s Republic of China ;23.Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, 200438, People’s Republic of China ; |
| Abstract: | Background Hepatocellular carcinoma (HCC) generally arises from a background of liver cirrhosis (LC). Patients with cirrhosis and suspected HCC are recommended to undergo serum biomarker tests and imaging diagnostic evaluation. However, the performance of routine diagnostic methods in detecting early HCC remains unpromising. MethodsHere, we conducted a large-scale, multicenter study of 1675 participants including 490 healthy controls, 577 LC patients, and 608 HCC patients from nine clinical centers across nine provinces of China, profiled gene mutation signatures of cell-free DNA (cfDNA) using Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) through detecting 931 mutation sites across 21 genes. ResultsAn integrated diagnostic model called “Combined method” was developed by combining three mutation sites and three serum biomarkers. Combined method outperformed AFP in the diagnosis of HCC, especially early HCC, with sensitivities of 81.25% for all stages and 66.67% for early HCC, respectively. Importantly, the integrated model exhibited high accuracy in differentiating AFP-negative, AFP-L3-negative, and PIVKA-II-negative HCCs from LCs. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |